Analytical assessment of ortho clinical diagnostics high-sensitivity cardiac troponin I assay
Peter A Kavsak1,2, Tara Edge3, Chantele Roy3
1McMaster University, Hamilton, ON, Canada.
Insights
The Ortho VITROS high-sensitivity cardiac troponin I assay shows excellent clinical performance for myocardial infarction detection. However, it yields lower results compared to other assays and has differences between serum and plasma. Standardization is needed.
Area of Science:
- Clinical Chemistry
- Cardiovascular Diagnostics
- Biomarker Assay Evaluation
Background:
- High-sensitivity cardiac troponin I (hs-cTnI) assays are crucial for diagnosing myocardial infarction (MI).
- Standardization across different manufacturers remains a challenge, impacting clinical interpretation.
Purpose of the Study:
- To analytically evaluate the Ortho Clinical Diagnostics VITROS hs-cTnI assay.
- To compare its performance in serum and lithium heparin (Li-Hep) plasma against other hs-cTnI assays.
Main Methods:
- Assessed limit of detection (LoD), imprecision, interference, and stability for the VITROS hs-cTnI assay in serum and Li-Hep plasma.
- Performed Passing-Bablok regression analyses and Receiver-operating characteristic (ROC) curve analyses in an emergency department (ED) population for MI detection.
Main Results:
- VITROS hs-cTnI assay demonstrated an LoD of 0.73 ng/L (serum) and 1.4 ng/L (Li-Hep).
- Serum showed superior analyte stability compared to Li-Hep plasma, which was also affected by hemolysis.
- The assay yielded proportionally lower concentrations in Li-Hep plasma (slope=0.85) and compared to other hs-cTnI assays in serum.
- Achieved an area under the curve (AUC) of 0.974 for MI detection in the ED study, comparable to other hs-cTn assays.
Conclusions:
- The VITROS hs-cTnI assay exhibits excellent clinical performance for MI detection, comparable to other hs-cTn assays.
- Significant differences exist between serum and Li-Hep plasma results, highlighting the need for matrix-specific interpretation.
- Lack of standardization among hs-cTnI assays necessitates further investigation and harmonization efforts.
Objectives:
To analytically evaluate Ortho Clinical Diagnostics VITROS high-sensitivity cardiac troponin I (hs-cTnI) assay in specific matrices with comparison to other hs-cTn assays.
Methods:
The limit of detection (LoD), imprecision, interference and stability testing for both serum and lithium heparin (Li-Hep) plasma for the VITROS hs-cTnI assay was determined. We performed Passing-Bablok regression analyses between sample types for the VITROS hs-cTnI assay and compared them to the Abbott ARCHITECT, Beckman Access and the Siemens ADVIA Centaur hs-cTnI assays. We also performed Receiver-operating characteristic curve analyses with the area under the curve (AUC) determined in an emergency department (ED)-study population (n=131) for myocardial infarction (MI).
Results:
The VITROS hs-cTnI LoD was 0.73 ng/L (serum) and 1.4 ng/L (Li-Hep). Stability up to five freeze-thaws was observed for the Ortho hs-cTnI assay, with the analyte stability at room temperature in serum superior to Li-Hep with gross hemolysis also affecting Li-Hep plasma hs-cTnI results. Comparison of Li-Hep to serum concentrations (n=202), yielded proportionally lower concentrations in plasma with the VITROS hs-cTnI assay (slope=0.85; 95% confidence interval [CI]:0.83-0.88). In serum, the VITROS hs-cTnI concentrations were proportionally lower compared to other hs-cTnI assays, with similar slopes observed between assays in samples frozen <-70 °C for 17 years (ED-study) or in 2020. In the ED-study, the VITROS hs-cTnI assay had an AUC of 0.974 (95%CI:0.929-0.994) for MI, similar to the AUCs of other hs-cTn assays.
Conclusions:
Lack of standardization of hs-cTnI assays across manufacturers is evident. The VITROS hs-cTnI assay yields lower concentrations compared to other hs-cTnI assays. Important differences exist between Li-Hep plasma and serum, with evidence of stability and excellent clinical performance comparable to other hs-cTn assays.
More Related Videos
09:23Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum
Published on: December 13, 2017
07:40Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training
Published on: October 10, 2019
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Myocarditis II: Clinical Features and Diagnostic Tests
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Receiver Operating Characteristic Plot
